Singapore Company Guide
Riverstone Holdings

Version 10 | Bloomberg: RSTON SP | Reuters: RVHL.SI **Refer to important disclosures at the end of this report**

DBS Group Research . Equity 26 Feb 2018

BUY (Upgrade from HOLD)

Last Traded Price (23 Feb 2018): S$1.04 (**STI :** 3,533.22)
Price Target 12-mth: S$1.27 (22% upside) (Prev S$1.09)

Analyst
Carmen Tay +65 6682 3719 carmentay@dbs.com

What's New

- Riverstone delivers record earnings in FY17 despite unfavourable forex; headline profits up 7.4% y-o-y to RM129.3m
- Core earnings outpaced output growth slightly (+17.1% vs 16.9% y-o-y), implying its strategy to grow the higher-margin cleanroom segment is paying off
- Riverstone can outperform peers amid industry headwinds as it ramps up on cleanroom glove capacity
- Upgrade to BUY with a higher TP of S$1.26

Price Relative



Forecasts and Valuation

FY Dec (RM m)	2016A	2017A	2018F	2019F
Revenue	655	817	934	1,055
EBITDA	169	186	230	260
Pre-tax Profit	139	151	178	199
Net Profit	120	129	154	173
Net Pft (Pre Ex.)	120	129	154	173
Net Pft Gth (Pre-ex) (%)	(4.9)	7.4	19.5	11.9
EPS (S cts)	5.46	5.86	7.01	7.84
EPS Pre Ex. (S cts)	5.46	5.86	7.01	7.84
EPS Gth Pre Ex (%)	(5)	7	19	12
Diluted EPS (S cts)	5.46	5.86	7.01	7.84
Net DPS (S cts)	2.19	2.36	2.82	3.15
BV Per Share (S cts)	25.1	28.8	33.0	37.6
PE (X)	19.1	17.7	14.8	13.3
PE Pre Ex. (X)	19.1	17.7	14.8	13.3
P/Cash Flow (X)	19.3	15.7	16.7	11.1
EV/EBITDA (X)	13.0	11.8	9.6	8.2
Net Div Yield (%)	2.1	2.3	2.7	3.0
P/Book Value (X)	4.1	3.6	3.2	2.8
Net Debt/Equity (X)	CASH	CASH	CASH	CASH
ROAE (%)	23.2	21.8	22.7	22.2
Earnings Rev (%):			0	6
Consensus EPS (S cts):			6.90	7.50
Other Broker Recs:		B: 1	S: 0	H: 2

Source of all data on this page: Company, DBS Bank, Bloomberg Finance L.P

Lifted by the semiconductor upcycle

Upgrade to BUY with TP of S$1.27 as we see earnings growing on strong cleanroom ramp-up. A global market leader in niche Class 10 and Class 100 cleanroom gloves, Riverstone's edge in the high-tech cleanroom segment sets it apart from the bigger boys. Given intense competition in the healthcare space, we see value in Riverstone's growing cleanroom business – which allows the group to command consistently higher margins vs peers (16% vs peers' c.10-15% in FY17).

With new cleanroom facilities set to kick in from 2Q18, cleanroom capacity is expected to grow by c.33% to at least 2bn gloves p.a. The ramp-up on these new capacities should help drive higher growth in cleanroom gloves vis-à-vis the lower-margin healthcare business, allowing Riverstone's earnings growth of c.16% to catch up with larger peers' c.17%.

Where we differ: We are more bullish vs consensus as we expect the improved output mix to help sustain margins and drive bottom line.

Potential catalysts: Further capacity expansion, sustained increase in cleanroom glove mix (and thus margins), and inorganic growth.

Capacity expansion and improving mix to underpin long-term growth. In anticipation of strong demand for both its cleanroom and healthcare gloves, Riverstone is now in the process of accelerating its expansion plans. Under its revised three-year expansion plan, we expect total glove production capacity to grow to 9bn pieces by end-2018 (vs 8.2bn previously) and 10.4bn pieces p.a. by end-2019.

Backed by robust demand and expectations of a higher cleanroom mix, we project earnings to grow at a c.16% CAGR from RM129m in FY17 to RM173m by FY19F.

Valuation:

Upgrade to BUY with TP of S$1.27, based on 16x FY19F PE. Underpinned by double-digit capacity growth and higher-quality earnings growth supported by more stable cleanroom margins, we believe that Riverstone deserves to at least trade at its historical average valuation of 16x FY19F PE, which represents a c.45% discount to larger peers' 29x.

Key Risks to Our View:

Global economic slowdown. While margins for cleanroom gloves tend to be resilient, demand for these gloves could be threatened in the event of a slowdown in the global economy.

At A Glance

Issued Capital (m shrs)	741
Mkt. Cap (Sm/USm)	771 / 584
Major Shareholders (%)	
Ringlet Investment Limited	50.8
Wai Keong Lee	10.9
Free Float (%)	33.5
3m Avg. Daily Val (US$m)	0.28
ICB Industry : Health Care / Health Care Equipment & Services	

WHAT'S NEW

Riverstone rises above persistent headwinds to deliver record-breaking FY17

Record RM129.3m profit in FY17. Riverstone delivered a decent set of 4Q17 results despite challenging operating conditions. Sales grew 12.2% q-o-q to c.RM210.7m on the back of capacity growth, but the unfavourable mix shift towards a higher proportion of lower-margin healthcare gloves resulted in relatively flat earnings of c.RM34.2m (vs RM34.3m in 3Q17).

On a full-year basis, the record sales and earnings of RM817.4m and RM129.3m were largely in line.

Higher dividend of 7 Scts for FY17 as Riverstone maintains a 40% payout, up 8% from 6.49 Scts in FY16.

Forex volatility a drag on strong core growth momentum. Volatility in the USD/MYR rate has weighed heavily on the sector's performance, Riverstone was not spared. In FY17, the group incurred net foreign exchange losses of c.RM13m, partly offset by hedging gains of c.RM6.8m as the company typically hedges c.50% of contracted sales.

Apart from the forex drag, Riverstone's core growth was otherwise strong, growing c.17.1% y-o-y to c.RM135.5m (vs c.RM115.8m in FY16):

(RM$ m)	FY16	FY17	%Chg (yoy)
Net Profit	120.4	129.3	*+7.4%*
Adjustments:			
Forex Loss (Gain)	(9.3)	13.0	
Fair Value Loss (Gain) on Derivatives	4.7	(6.7)	
Adjusted Net Profit	115.8	135.5	*+17.1%*

Source: Company, DBS Bank

Plans to further cultivate cleanroom business starting to pay off. Taking into account Riverstone's temporary operational hiccup in 3Q which affected its production ramp, we observe that core earnings momentum has in fact outpaced output growth at 17.1% vs 16.9% respectively, implying that plans to further grow cleanroom sales are starting to bear fruit.

While dipping lines can be used interchangeably between healthcare and cleanroom gloves, the latter typically undergo additional secondary processes in specialised cleanroom facilities. Discussions during the 3Q17 and 4Q17 results briefing revealed that utilisation for these facilities have improved by >20% q-o-q to nearly 100% currently, which further supports our view that the cleanroom segment is starting to see stronger growth vs the healthcare segment.

Anticipate weaker 1Q18 as headwinds persist, but stronger growth to kick in from 2Q18. With operating conditions little changed, we expect industry headwinds – fluctuations in USD/MYR, volatile raw material prices and operating costs – to remain a bane for the glove industry at large. Further, with the revised foreign worker levy policy and gas price hike coming into force in January 2018, we anticipate 1Q18 results to be weak across the industry.

All else equal, underpinned by a c.33% increase in cleanroom capacity to at least 2bn by end-2Q18, Riverstone is set to see stronger growth ahead. Full contribution from these incoming cleanroom capacities will likely only come in from FY19 as the group ramps up on production progressively.

Riverstone due for a re-rating. While shares of larger peers – Kossan, Hartalega and Top Glove have re-rated strongly in recent months, Riverstone's strengths remain underappreciated. Based on consensus estimates, Hartalega currently trades at +1SD of its historical forward PE valuations, Top Glove and Kossan above +2SD. Meanwhile, Riverstone continues to trade below its historical average forward PE. As a result, Riverstone's discount gap has widened significantly vs peers, from c.28% to 49% currently.

Underpinned by capacity growth at c.17% CAGR (vs larger peers' average of c.15.2%) over FY17-19 and higher-quality earnings growth supported by more defensible margins, we believe that Riverstone deserves to at least trade at its historical average valuation of 16x FY19F PE (c.45% discount to larger peers' 29x) as earnings growth catches up. Better-than-expected execution on these incoming capacities could spark a further re-rating to 18x FY19F PE (+1SD), in line with peers.

Upgrade to BUY with a higher TP of S$1.27, based on 16x FY19F PE. Post 4Q17, we assume higher margins on a more favourable product mix, and partly offset by lower ASPs resulting from the recent forex weakness, we raise our FY19F earnings projections by c.6% to RM172.8m. After rolling forward our earnings base to FY19F to better capture the strong growth potential from the roll-out of incoming cleanroom capacities, and pegging to historical average forward valuation of 16x, we arrive at a higher TP of S$1.27 (vs S$1.09 previously). Upgrade to BUY.

Quarterly / Interim Income Statement (RMm)

FY Dec	4Q2016	3Q2017	4Q2017	% chg yoy	% chg qoq
Revenue	183	188	211	15.1	12.2
Cost of Goods Sold	(135)	(137)	(159)	18.1	16.2
Gross Profit	48.2	50.8	51.5	6.8	1.3
Other Oper. (Exp)/Inc	(6.8)	(10.9)	(11.0)	61.7	0.8
Operating Profit	41.4	40.0	40.5	(2.2)	1.4
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	-	-
Associates & JV Inc	0.0	0.0	0.0	-	-
Net Interest (Exp)/Inc	0.0	(0.3)	(0.3)	nm	6.7
Exceptional Gain/(Loss)	0.0	0.0	0.0	-	-
Pre-tax Profit	41.4	39.7	40.3	(2.8)	1.5
Tax	(5.4)	(5.3)	(6.0)	11.8	13.3
Minority Interest	0.0	0.0	0.0	-	-
Net Profit	36.0	34.3	34.2	(5.0)	(0.3)
Net profit bef Except.	36.0	34.3	34.2	(5.0)	(0.3)
EBITDA	49.7	48.3	48.9	(1.7)	1.2
Margins (%)					
Gross Margins	26.3	27.1	24.4		
Opg Profit Margins	22.6	21.3	19.2		
Net Profit Margins	19.7	18.3	16.2		

Source of all data: Company, DBS Bank

CRITICAL DATA POINTS TO WATCH

Critical Factors

Growth in global demand for healthcare gloves, at least in near to medium term. The Malaysian Rubber Glove Manufacturers Association (MARGMA) estimates that demand for healthcare gloves is likely to grow at 8-12% p.a. between 2014 and 2020.

As a relatively new entrant in the healthcare glove industry and with ambitions to grow revenue from this segment quickly to drive its earnings, we project a ramp-up in Riverstone's healthcare glove production at a 17.5% CAGR over FY17-19F.

Long-term trends also indicate favourable demand prospects. According to MARGMA, the global demand ratio of natural rubber and synthetic (nitrile) rubber gloves shifted from 74:26 in 2009 to 53:47 in 2014. On the back of rising awareness of latex allergies in emerging economies and the synthetic variety's low cost, we expect the ratio to shift away from natural rubber gloves in the long run.

Riverstone could be a beneficiary of the long-run substitution of rubber gloves and PVC gloves (especially for the cleanroom segment) by nitrile gloves as it is principally engaged in the production of the latter.

Capacity expansion to underpin growth. To capitalise on the favourable demand growth outlook in both the short and long term, Riverstone guided that it now expects to expand its manufacturing capacity to a minimum of 7.6bn gloves by end-2017, 9bn gloves by end-2018 and 10.4bn gloves by end-2019, as compared to 8.2bn gloves by 2018 previously.

We expect new production capacities to propel top-line growth at a CAGR of 13.6% between FY17 and FY19F, as they gradually come on stream.

Higher proportion of cleanroom gloves. As Riverstone's glove production lines can be used interchangeably for both healthcare and higher-margin cleanroom glove production, priority is typically given to cleanroom glove orders.

With demand in the niche cleanroom segment mainly stemming from the semiconductor and mobile tablet sectors, we see Riverstone as an indirect beneficiary of the current semiconductor upcycle. Given the current competitive landscape within the healthcare glove space, a higher sustained proportion of cleanroom glove production could help Riverstone better defend margins vs peers (which are predominantly focused in the production of healthcare gloves).

Greater efficiency from higher automation and larger scale should help to maintain margins. Despite competition and pressure on ASPs, we expect automation efforts and Riverstone's growing economies of scale to help shore up and sustain operating margins above 19%, to support stable growth in net profit ahead.

Capital Expenditure (RM$m)



Production Capacity (m gloves)



Cleanroom Gloves (m gloves)



Healthcare Gloves (m gloves)



Operating Margins (%)



Source: Company, DBS Bank

Balance Sheet:

Healthy balance sheet. In 1Q17, the company took on debt for the first time in five years to fund its upcoming expansion plans. Despite this, we note that Riverstone remained in a net cash position of RM89.3m as at end 4Q17.

Forecast net fixed asset growth at a CAGR of 10% between 2015 and 2019. As capacity is expected to double in 2019 from 2015 levels, we project the group's net fixed assets to jump by nearly 50% from RM286m in 2015 to RM419m in 2018.

Share Price Drivers:

Opportunities for inorganic growth. Due to the stringent requirements for the establishment of cleanroom facilities, Riverstone does not rule out the possibility of acquiring quality cleanroom glove manufacturing companies in the future.

Cultivation of new markets for cleanroom products. As cleanroom products are manufactured in controlled environments and are subject to stringent requirements, they are able to deliver much higher margins relative to healthcare gloves. The ability to cultivate new markets for cleanroom products, similar to what Riverstone recently achieved with its diversification into the consumer electronics sector, should help to boost earnings.

An acceleration of capacity expansion plans beyond the current guidance of 10.4bn gloves by end-2019 could drive a further re-rating of share price.

Key Risks:

Global economic slowdown could impact cleanroom sales. A slowdown in the general economy could lead to declines in discretionary spending and manufacturing activity in the HDD industry. Although Riverstone has been gradually reducing its exposure to HDDs, down from historical highs of up to 70%, they still make up less than 50% of the company's cleanroom portfolio today.

Intensifying competition could erode profitability. We believe that oversupply over the next few years is unlikely given the more balanced demand-supply outlook for healthcare gloves among Malaysian peers compared to a year ago. However, rising competition from budding glove manufacturing regions such as Thailand and China could threaten Riverstone's market share and pricing power later on if it fails to advance on the technological front.

Company Background

Riverstone Holdings (RSTON SP) is a natural rubber and nitrile (synthetic rubber) glove manufacturer specialising in cleanroom and healthcare gloves. It is also engaged in the manufacture and distribution of other ancillary products such as finger cots, packaging bags and face masks.

Leverage & Asset Turnover (x)



Capital Expenditure



ROE (%)



Forward PE Band (x)

PB Band (x)



Source: Company, DBS Bank

Key Assumptions

FY Dec	2015A	2016A	2017A	2018F	2019F
Capital Expenditure	54.2	94.3	110	75.0	75.0
Production Capacity (m	3,942	5,252	6,371	7,590	8,924
Cleanroom Gloves (m	985	1,014	1,274	1,609	1,892
Healthcare Gloves (m	2,956	4,238	5,097	5,981	7,032
Operating Margins (%)	25.8	21.2	18.6	19.3	19.2

Income Statement (RMm)

FY Dec	2015A	2016A	2017A	2018F	2019F
Revenue	560	655	817	934	1,055
Cost of Goods Sold	(385)	(482)	(620)	(702)	(795)
Gross Profit	175	173	198	233	260
Other Opng (Exp)/Inc	(30.5)	(34.3)	(45.9)	(52.8)	(57.2)
Operating Profit	144	139	152	180	202
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	0.0	0.0	(1.0)	(1.8)	(3.0)
Exceptional Gain/(Loss)	0.0	0.0	0.0	0.0	0.0
Pre-tax Profit	144	139	151	178	199
Tax	(17.8)	(18.5)	(21.5)	(23.7)	(26.6)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Preference Dividend	0.0	0.0	0.0	0.0	0.0
Net Profit	127	120	129	154	173
Net Profit before Except.	127	120	129	154	173
EBITDA	169	169	186	230	260
Growth					
Revenue Gth (%)	40.3	16.9	24.8	14.3	12.9
EBITDA Gth (%)	68.4	(0.3)	10.5	23.6	12.8
Opg Profit Gth (%)	78.0	(3.8)	9.4	18.5	12.4
Net Profit Gth (Pre-ex) (%)	78.4	(4.9)	7.4	19.5	11.9
Margins & Ratio					
Gross Margins (%)	31.2	26.4	24.2	24.9	24.6
Opg Profit Margin (%)	25.8	21.2	18.6	19.3	19.2
Net Profit Margin (%)	22.6	18.4	15.8	16.5	16.4
ROAE (%)	29.7	23.2	21.8	22.7	22.2
ROA (%)	24.7	19.2	17.9	18.4	17.6
ROCE (%)	28.8	22.7	20.7	20.6	19.1
Div Payout Ratio (%)	37.8	40.0	40.2	40.2	40.2
Net Interest Cover (x)	NM	138,849.0	148.4	100.0	67.4

Source: Company, DBS Bank

Quarterly / Interim Income Statement (RMm)

FY Dec	4Q2016	1Q2017	2Q2017	3Q2017	4Q2017
Revenue	183	206	213	188	211
Cost of Goods Sold	(135)	(154)	(170)	(137)	(159)
Gross Profit	**48.2**	**51.8**	**43.7**	**50.8**	**51.5**
Other Oper. (Exp)/Inc	(6.8)	(12.4)	(11.7)	(10.9)	(11.0)
Operating Profit	**41.4**	**39.4**	**32.0**	**40.0**	**40.5**
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Associates & JV Inc	0.0	0.0	0.0	0.0	0.0
Net Interest (Exp)/Inc	0.0	(0.2)	(0.3)	(0.3)	(0.3)
Exceptional Gain/(Loss)	0.0	0.0	0.0	0.0	0.0
Pre-tax Profit	**41.4**	**39.2**	**31.7**	**39.7**	**40.3**
Tax	(5.4)	(5.6)	(4.6)	(5.3)	(6.0)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Net Profit	**36.0**	**33.6**	**27.1**	**34.3**	**34.2**
Net profit bef Except.	36.0	33.6	27.1	34.3	34.2
EBITDA	49.7	47.6	40.3	48.3	48.9
Growth					
Revenue Gth (%)	9.6	12.4	3.7	(11.9)	12.2
EBITDA Gth (%)	19.4	(4.2)	(15.3)	19.8	1.2
Opg Profit Gth (%)	21.7	(5.0)	(18.8)	25.0	1.4
Net Profit Gth (Pre-ex) (%)	20.8	(6.7)	(19.5)	26.8	(0.3)
Margins					
Gross Margins (%)	26.3	25.2	20.5	27.1	24.4
Opg Profit Margins (%)	22.6	19.1	15.0	21.3	19.2
Net Profit Margins (%)	19.7	16.3	12.7	18.3	16.2

Balance Sheet (RMm)

FY Dec	2015A	2016A	2017A	2018F	2019F
Net Fixed Assets	277	337	420	444	462
Invts in Associates & JVs	0.0	0.0	0.0	0.0	0.0
Other LT Assets	9.61	8.62	9.74	9.74	9.74
Cash & ST Invts	129	103	114	165	277
Inventory	61.2	67.0	71.1	71.4	80.8
Debtors	103	140	145	187	211
Other Current Assets	6.06	11.9	20.9	20.9	20.9
Total Assets	**585**	**668**	**781**	**898**	**1,062**
ST Debt	0.0	0.0	6.00	6.00	6.00
Creditor	84.4	90.5	102	76.7	86.9
Other Current Liab	7.65	9.92	8.45	8.45	8.45
LT Debt	0.0	0.0	19.0	69.0	119
Other LT Liabilities	11.7	12.7	11.2	11.2	11.2
Shareholder's Equity	482	555	634	727	830
Minority Interests	0.0	0.0	0.01	0.01	0.01
Total Cap. & Liab.	**585**	**668**	**781**	**898**	**1,062**
Non-Cash Wkg. Capital	78.2	119	127	194	217
Net Cash/(Debt)	129	103	89.3	89.8	152
Debtors Turn (avg days)	61.8	67.8	63.7	64.8	68.8
Creditors Turn (avg days)	68.3	70.7	60.0	50.0	40.5
Inventory Turn (avg days)	52.3	51.8	43.1	39.9	37.7
Asset Turnover (x)	1.1	1.0	1.1	1.1	1.1
Current Ratio (x)	3.2	3.2	3.0	4.9	5.8
Quick Ratio (x)	2.5	2.4	2.2	3.9	4.8
Net Debt/Equity (X)	CASH	CASH	CASH	CASH	CASH
Net Debt/Equity ex MI (X)	CASH	CASH	CASH	CASH	CASH
Capex to Debt (%)	N/A	N/A	441.1	100.0	60.0
Z-Score (X)	16.6	15.4	14.7	14.7	10.9

Source: Company, DBS Bank

Cash Flow Statement (RMm)

FY Dec	2015A	2016A	2017A	2018F	2019F
Pre-Tax Profit	144	139	151	178	199
Dep. & Amort.	24.8	29.9	34.5	50.4	57.7
Tax Paid	(18.5)	(22.6)	(21.3)	(23.7)	(26.6)
Assoc. & JV Inc/(loss)	0.0	0.0	0.0	0.0	0.0
Chg in Wkg.Cap.	(26.3)	(31.8)	(11.6)	(67.3)	(23.4)
Other Operating CF	(2.3)	4.65	(6.8)	0.0	0.0
Net Operating CF	**122**	**119**	**146**	**138**	**207**
Capital Exp.(net)	(54.2)	(94.3)	(110)	(75.0)	(75.0)
Other Invts.(net)	0.0	(2.3)	0.0	0.0	0.0
Invts in Assoc. & JV	0.0	0.0	0.0	0.0	0.0
Div from Assoc & JV	0.0	0.0	0.0	0.0	0.0
Other Investing CF	0.0	0.0	0.0	0.0	0.0
Net Investing CF	**(54.2)**	**(96.6)**	**(110)**	**(75.0)**	**(75.0)**
Div Paid	(25.8)	(48.5)	(48.1)	(62.1)	(69.5)
Chg in Gross Debt	0.0	0.0	25.0	50.0	50.0
Capital Issues	0.0	0.0	0.0	0.0	0.0
Other Financing CF	0.0	0.0	0.0	0.0	0.0
Net Financing CF	**(25.8)**	**(48.5)**	**(23.1)**	**(12.1)**	**(19.5)**
Currency Adjustments	7.07	0.65	(1.3)	0.0	0.0
Chg in Cash	49.2	(25.5)	11.1	50.5	113
Opg CFPS (S cts)	6.73	6.84	7.13	9.29	10.5
Free CFPS (S cts)	3.08	1.12	1.61	2.84	5.99

Source: Company, DBS Bank

Target Price & Ratings History

S.No.	Date of Report	Closing Price	12-mth Target Price	Rating
1:	24 Feb 17	0.92	0.92	HOLD
2:	05 May 17	0.97	1.07	BUY
3:	17 Jul 17	1.05	1.07	BUY
4:	04 Aug 17	1.05	1.07	BUY
5:	07 Aug 17	1.06	1.09	HOLD
6:	08 Nov 17	1.07	1.09	HOLD

***Note** : Share price and Target price are adjusted for corporate actions.*

Source: DBS Bank
Analyst: Carmen Tay

DBS Bank recommendations are based an Absolute Total Return* Rating system, defined as follows:
STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)
BUY (>15% total return over the next 12 months for small caps, >10% for large caps)
HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)
FULLY VALUED (negative total return i.e. > -10% over the next 12 months)
SELL (negative total return of > -20% over the next 3 months, with identifiable catalysts within this time frame)

Share price appreciation + dividends

Completed Date: 26 Feb 2018 08:01:40 (SGT)
Dissemination Date: 26 Feb 2018 08:56:54 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate[1] does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests[2] in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS''), DBSV HK or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 31 Jan 2018.

2. Neither DBS Bank Ltd, DBS HK nor DBSV HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS''), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS''), their subsidiaries and/or other affiliates in the preceding 12 months.

[1] An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

[2] Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd. (“DBS”) or DBS Vickers Securities (Singapore) Pte Ltd (“DBSVS”). DBS holds Australian Financial Services Licence no. 475946. DBSVS is exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 (“CA”) in respect of financial services provided to the recipients. DBSVS is regulated by the Monetary Authority of Singapore under the laws of Singapore, which differ from Australian laws. Distribution of this report is intended only for “wholesale investors” within the meaning of the CA.
Hong Kong	This report has been prepared by a person(s) who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Vickers Hong Kong Limited, a licensed corporation licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). For any query regarding the materials herein, please contact Paul Yong (CE. No. ASE988) at equityresearch@dbs.com.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies. Wong Ming Tek, Executive Director, ADBSR
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at PO Box 506538, 3rd Floor, Building 3, East Wing, Gate Precinct, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.

United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

DBS Regional Research Offices

HONG KONG
DBS Vickers (Hong Kong) Ltd
Contact: Paul Yong
18th Floor Man Yee Building
68 Des Voeux Road Central
Central, Hong Kong
Tel: 65 6878 8888
Fax: 65 65353 418
e-mail: equityresearch@dbs.com
Participant of the Stock Exchange of Hong Kong

MALAYSIA
AllianceDBS Research Sdn Bhd
Contact: Wong Ming Tek (128540 U)
19th Floor, Menara Multi-Purpose,
Capital Square,
8 Jalan Munshi Abdullah 50100
Kuala Lumpur, Malaysia.
Tel.: 603 2604 3333
Fax: 603 2604 3921
e-mail: general@alliancedbs.com

SINGAPORE
DBS Bank Ltd
Contact: Janice Chua
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888
Fax: 65 65353 418
e-mail: equityresearch@dbs.com
Company Regn. No. 196800306E

INDONESIA
PT DBS Vickers Sekuritas (Indonesia)
Contact: Maynard Priajaya Arif
DBS Bank Tower
Ciputra World 1, 32/F
Jl. Prof. Dr. Satrio Kav. 3-5
Jakarta 12940, Indonesia
Tel: 62 21 3003 4900
Fax: 6221 3003 4943
e-mail: research@id.dbsvickers.com

THAILAND
DBS Vickers Securities (Thailand) Co Ltd
Contact: Chanpen Sirithanarattanakul
989 Siam Piwat Tower Building,
9th, 14th-15th Floor
Rama 1 Road, Pathumwan,
Bangkok Thailand 10330
Tel. 66 2 857 7831
Fax: 66 2 658 1269
e-mail: research@th.dbs.com
Company Regn. No 0105539127012
Securities and Exchange Commission, Thailand